Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 4/20 | 0.53 |
| ▸ | CA2 | P00918 | 12/20 | 0.51 |
| ▸ | CA1 | P00915 | 11/20 | 0.51 |
| ▸ | CA12 | O43570 | 9/20 | 0.51 |
| ▸ | CA9 | Q16790 | 9/20 | 0.51 |
| ▸ | CA7 | P43166 | 5/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2740677 | 0.86 | ELANE (0.54) | ELANEALDH1A1 | |
| SCHEMBL31531294 | 0.83 | ELANE (0.74) | ELANECA2CA1CA12CA9 | |
| SCHEMBL2740712 | 0.82 | ELANE (0.50) | ELANECA2CA1ALDH1A1HTT | |
| SCHEMBL92310 | 0.80 | ELANE (0.56) | ELANEALDH1A1MEN1KMT2A | |
| SCHEMBL20465906 | 0.80 | ELANE (0.48) | ELANE | |
| SCHEMBL17052470 | 0.79 | ELANE (0.49) | ELANEALDH1A1MEN1KMT2A | |
| SCHEMBL12736997 | 0.78 | ELANE (0.58) | ELANECA2CA1ALDH1A1MEN1 | |
| SCHEMBL13563645 | 0.78 | ELANE (0.58) | ELANEALDH1A1MEN1KMT2A | |
| SCHEMBL12736999 | 0.78 | ELANE (0.54) | ELANEALDH1A1MEN1KMT2A | |
| SCHEMBL13702459 | 0.78 | ELANE (0.49) | ELANECA2CA1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023224240-A1 | POLYMER COMPOUND COMPRISING SULFONYL AZIDE GROUP OR SULFONYL FLUORIDE GROUP AT CHAIN END AND PREPARATION METHOD THEREFOR | 아주대학교산학협력단 | 2023-11-23 | — | — | WO | disclosed |
| US-20120146264-A1 | RESIN COMPOSITION FOR LASER ENGRAVING, RELIEF PRINTING PLATE PRECURSOR FOR LASER ENGRAVING AND PROCESS FOR PRODUCING SAME, AND PROCESS FOR MAKING RELIEF PRINTING PLATE | FUJIFILM CORPORATION (JP) | 2012-06-14 | — | — | US | disclosed |
| US-8101332-B2 | Negative-working lithographic printing plate precursor and method of lithographic printing using same | FUJIFILM CORPORATION (JP) | 2012-01-24 | — | — | US | disclosed |
| US-20090246688-A1 | NEGATIVE-WORKING LITHOGRAPHIC PRINTING PLATE PRECURSOR AND METHOD OF LITHOGRAPHIC PRINTING USING SAME | FUJIFILM CORPORATION (JP) | 2009-10-01 | — | — | US | disclosed |
| US-20080233516-A1 | NEGATIVE LITHOGRAPHIC PRINTING PLATE PRECURSOR AND LITHOGRAPHIC PRINTING METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-09-25 | — | — | US | disclosed |
| US-7179582-B2 | Radical polymerizable composition and lithographic printing plate precursor using the same | FUJI PHOTO FILM CO., LTD. (JP) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120146264-A1 | RESIN COMPOSITION FOR LASER ENGRAVING, RELIEF PRINTING PLATE PRECURSOR FOR LASER ENGRAVING AND PROCESS FOR PRODUCING SAME, AND PROCESS FOR MAKING RELIEF PRINTING PLATE | EIF3L, EIF2B1, EIF2B5 | ELANE 1342/4885CA2 1712/4885CA1 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.